~/oj 3i. Qualification Qualification of analytical instrumentation is essential for accurate and precise measurement of analytical data.

Size: px
Start display at page:

Download "~/oj 3i. Qualification Qualification of analytical instrumentation is essential for accurate and precise measurement of analytical data."

Transcription

1 David A. Porter This article considers the distinction among the terms qualification, validation, and verification in the context of pharmacopeial usage. A recommendation for a standardized usage of the terms validation and verification is provided, and general requirements for validation and verification activities are given.the article also emphasizes the importance of knowing when validation or verification is necessary relative to the use of a method to satisfy pharmacopeial article requirements (for which a monograph exists in the pharmacopeia) or for nonpharmacopeial use. David A. Porter is a pharmaceutical consultant with Vectech Pharmaceutical Consultants, Inc. (Farmington, MI), dporte&vectech.com Submitted: Oct. 26,2006. Accepted: Dac Keywords: qualification, USE validation, verifmtion 146 Pihmcervtical lechnolog~ APRIL 2007 ~/oj 3i T he terms qualification, validation, and verification occur numerous times in US Pharrnacopeia 29 (1). Qualification is found in Chapters (1035) "Biological Indicators for Sterilization," (1043) "Ancillary Materials Cell, Gene, and Tissue-Engineered Products," (1046) "Cell and Gene Therapy Products," and (1119)"Near-Infrared Spectrophotometry," among others. Validation appears in (1225) "Validation of Compendia1 Procedures," (1223) "Validation of Alternative Microbiological Methods," (1010) "Analytical Data-Interpretation and Treatment," (1043)"Ancillary Materials for Cell-, Gene-, and Tissue-Engineered Products," (1117)"Microbiological Best Laboratory Practices," (1120) "Raman Spectrophotometry," and many others. Verification appears in (1010)"Analytical Data-Interpretation and Treatment," (1035)"Biological Indicators for Sterilization," (1035) "Biological Indicators for Sterilization," (85) "Bacterial Endotoxins Test," and others. The terms also are present in documents from the US Food and Drug Administration, the Environmental Protection Agency (EPA), and the International Conference on Harmonization (ICH). Given the numerous definitions for the three terms, this article in part is intended to provide an approach to fostering more consistency in the usage of the terms. A recent issue of the Pharmacopeial Forum (2) had a diagram from a proposed General Chapter (1058) "Analytical Instrument Qualification" that was intended to show "...four critical components involved in the generation of reliable and consistent data (quality data)." From most to least critical, the components were quality-control check samples, system suitability tests, analytical methods validation, and analytical instrument qualification. In this article, consider systemsuitability tests to be the same as verification. Why this usage should be acceptable will be explained. This article will consider validation and verification in detail. Reference to analytical instrument qualification is made. For further discussion of the top tier, "Quality Control Check Samples," refer to Chapter (1058)"Analytical Instrument Qualification" (1). Qualification Qualification of analytical instrumentation is essential for accurate and precise measurement of analytical data. If the

2 instrumentation is not qualified, ensuring that the results indicated are trustworthy, all other work based upon the use of that instrumentation is suspect. For the purposes of this article, the assumption will be made that the foundation of validation and verification work to follow is based solidly upon well-qualified instrumentation. Validation Definitions.Numerous documents provide definitions of validation. A dictionary definition (3) of validation includes "...the process of determining the degree of validity of a measuring device," and for validate: "to make legally valid," with synonyms "verify, substantiate." Clearly, the synonyms do not distinguish between validation and verification, so let us now turn to definitions provided by other sources. USP chapter (1225) "Validation of Compendia1 Procedures" provides the following: Validation of an analytical procedure is the process by which it is established, by laboratory studies, that the performance characteristics of the procedure meet the requirements for the intended analytical applications. From the ICH document Validation ofanalytica1 Procedures: Text and Methodology: However, it is important to remember that the main objective of validation of an analytical procedure is to demonstrate that the procedure is suitable for its intended purpose (4). FDA provides a definition of validation in numerous documents. One such document, Guidance for Industry: Analytical Procedures and Methods Validation Chemistry, Manufacturing, and Controls Documentation says "methods validation is the process of demonstrating that analytical procedures are suitable for their intended use"(5). There also are numerous documents defining validation within the context of processes. From FDA's Guideline on General Principles of Process Validation: Validation-Establishing documented evidence which provides a high degree of assurance that a specific process will consistently produce a product meeting its predetermined specifications and quality attributes (6). The same definition is provided in other FDA documents, such as Guideline on Sterile Drug Products Produced by Aseptic Processing. FDA document Guidance for Industry: Quality Systems Approach to Pharmaceutical Current Good Manufacturing Practice Regulations provides this definition: f 48 With proper design (see section IV.C.l), and reliable mechanisms to transfer process knowledge from development to commercial production, a manufacturer should be able to validate the manufacturing process. In a quality system, process validation provides initial proof, through commercial batch manufacture, that the design of the process produces the intended product quality (7). h ~ i c TechnoIopy ~ l APRIL 2007 The remainder of the discussion about validation in this article will be restricted to a discussion of method validation. Does it suit its purpose? The foregoing is clearly not an exhaustive list of the manners in which validation has been defined. It does appear that a recurring theme among the various definitions pertains to demonstrating that the method or process is suitable for its intended use. In this article, consider validation to be the demonstration that a method or process is suitable for its intended purpose. Accepting that, it is imperative that the intended purpose of a method or process is clearly stated at the outset of the validation. An example of the importance of such a statement can be found in Chapter (71) "Sterility Tests" (1). It states that "the following procedures are applicable for determining whether a Pharmacopeial article purporting to be sterile complies with the requirements set forth in the individual monograph with respect to the test for sterility." The next paragraph states These Pharmacopeial procedures are not by themselves designed to ensure that a batch of product is sterile or has been sterilized. This is accomplished primarily by validation of the sterilization process or of the aseptic processing procedures. During the years there has been concern that the tests for sterility as provided in Chapter (71) are not adequate to prove that a batch of product is sterile. As stated previously, the tests in Chapter (71) were intended only to show that a Pharmacopeial article is sterile. Such a demonstration constitutes a necessary but not sufficient condition for sterile pharmacopeial articles. If one were to validate an alternative procedure for that in Chapter (71), it would not be necessary to develop one that is intended to demonstrate sterility of an entire lot of product. In addition, it is appropriate that the conditions are provided under which the validation was performed. Given that there are essentially countless variations on experimental conditions, product matrix effects, and so forth, a validation cannot reasonably expect to address all such permutations. For example, Method 3 in the section of Chapter (1047) "Biotechnology-Derived Article-Tests", which addresses assays for total protein, indicates in a note: [Do not use quartz (silica) spectrophotometer cells: the dye bids to this material. Because different protein species may give different color response intensities, the standard protein and test protein should be the same.] There are relatively few interfering substances, but detergents and ampholytes in the test specimen shodd be avoided. Highly alkaline specimens may interfere with the acidic reagent (1). Therefore, given the following from FDA's Guide to Inspections of Pharmaceutical Quality Control Laboratories: "Methods appearing in the USP are considered validated and they are considered validated if part of an approved ANDA" (S), the use of Method 3 would be valid if the conditions stated

3 I A Quality Analytical methods validation Analytical instrument qualification Figure 1: The order of processes. are met in testing the material of interest. The same FDA document states "For compendia1 methods, firms must demonstrate that the method works under the actual conditions of use," which, for the sake of this article, will be considered verification. Chapter (1047) provides several other procedures, all also validated, that could be considered given test material that does not satisfy the conditions for Method 3. Rememberthe purpose. It is important to bear in mind the purpose of the method to be validated. If the method is intended to serve as an alternative to a pharmacopeial method, then one must establish its equivalence to the pharmacopeial method in terms of the end result. Remember that the purpose of a method in the pharmacopeia is to determine whether the pharmacopeial article (for which a monograph exists in the pharmacopeia) satisfies the requirements in the monograph. If instead the purpose behind the use of a pharmacopeial method is for a purpose other than demonstrating that the article complies with monograph requirements (for example, imagine that total organic carbon is to be determined using Chapter (643) "Total Organic Carbon"), it is not necessary to perform the validation relative to the pharmacopeial results. This means that the validation should be conducted relative to the specific purpose for which it is intended. Also implicit in this is the use of a nonpharmacopeial method to determine something for which a pharmacopeial method exists, but again for purposes unrelated to satisfying a monograph requirement. In such a case, it is unnecessary to consider vahdating the method relative to that in the pharmacopeia. Verification If the use of the term validation is restricted to mean the demonstration of suitability of a method or process for its intended purpose, and the term verification for the demon- use given specific experimental conditions that may or may not be appropriate given the conditions present during the validation, the terminological situation may be clarified. These actual conditions include specific ingredients or products, specific laboratory personnel, equipment, and reagents. There are, however, instances in the literature where this distinction is not maintained. Consider the dictionary definition given previously for validation and its use of verification as a synonym for validation. Further muddying of the waters occurs when phrases such as "system suitability tests" (see Figure 1 and the system-suitability section in Chapter (621) "Chromatography"). The phrase also appears in the "Suitability of the Counting Method in the Presence of Product" section of Chapter (61) "Microbiological Examination of Nonsterile Products: Microbial Enumeration Tests'', the "Suitability of the Test Method section of Chapter (62) "Microbiological Examination of Nonsterile Products: Tests for Specified Microorganisms", and the "Validation Test" section of Chapter (71) "Sterility Tests." (1). In all cases, the intention is to ensure that the validated method will work under the specific conditions the analyst plans to use. This means that a chromatographic system can deliver resolution and reproducibility on par with the system used during validation. For the two microbiology test chapters for nonsterile products, one must show that microbial growth in the presence of the article to be tested is not hindered. This is because the method depends on unencumbered microbial growth for it to work. In other words, a condition established in validating the method initially was unhindered microbial growth. The use of "validation test" in Chapter (71) is unfortunate because the intention was again to demonstrate that microbial growth is not hindered, as indicated in the following text: If clearly visible growth of microorganisms is obtained after the incubation, visually comparable to that in the control vessel without product, either the product possesses no antimicrobial activity under the conditions of the test or such activity has been satisfactorily eliminated. The test for sterility may then be carried out without further modification. It may be advantageous, and more consistent, for the text in Chapter (71) to be changed to "Suitability of the Test Method," if not to "Verification of the Test Method." The latter change also may be appropriate for Chapters (61) and (62), given that what is being assessed is the verification that the actual test conditions relative to those established during the validation permits the proper functioning of the method.. Given the harmonized status of these three chapters, such changes, although possible, would certainly take longer to become official. The same cautions provided at the end of the section on validation are applicable here. If a method in use previously was derived from a pharmacopeial method but used for a 150 Pharmaceutical Techfl010jy APRIL 2007

4 purpose other than satisfying monograph requirements, it is not necessary to adopt a revised method in the pharmacopeia when it becomes official. It is therefore not necessary to reverify the suitability of your test article to the revised method. Likewise, the use of a nonpharmacopeial method for purposes other than satisfying a monograph requirement when a pharmacopeial method exists of potential relevance does not necessitate reverification. General requirements for validation There are numerous documents that describe the general approach to a validation process. They describe several characteristics (data elements in Chapter (1225)) that may be examined during validation, with specific sets selected based upon the nature of the test method. A brief description of these characteristics is provided herein using the characteristics as outlined in the IC Harmonization Harmonized Tripartite Guideline, Validation of Analytical Procedures: Text and Methodology Accuracy is a determination of how close the measured value is (in the case of an analytical method) to the true value. As such, one might define accuracy of method as equal to true value plus error. Error may contain both the systematic error (bias) and imprecision of measurement. With the potential error possible, it is important to include a means of reflecting the "true value" as closely as possible. For many compendial tests, this involves the use of a reference standard. Because a method is expected to be useful over a range of true values, the accuracy should be assessed over the expected range of values to which the method is to be applied. As stated previously, the validation should also state the conditions under which the accuracy was determined. Because it is not possible to determine all possible sets of conditions for which a compendial assay might be applicable, accuracy may need to be verified before use of a validated method. The concept of accuracy is more problematic for microbiological assays. The precision of a method determined during validation should be representative of the repeatability (reproducibility) of the method. As was the case for the determination of accuracy, it should be determined over the expected range of articles to be measured, and the conditions used during the validation should be clearly stated. As for accuracy, the use of reference standards is common because the goal of the assessment of precision is to determe method repeatability without introducing unknown variance as a result of different test articles or test articles drawn from a heterogeneous source. The latter point also complicates the validation of microbiological assays. Specificity refers to the ratio of false positives to false negatives. A highly specific method would have a very low ratio, given that it should be able to detect the article of interest present in very low quantities in the presence of much higher quantities of similar but not identical articles. As stated previously, specificity should be determined over the expected range of usage for the method, and conditions used during the validation should be clearly stated. Linearity, in essence, refers to the existence of a direct relationship between the quantity of article contained in the sanlple being analyzed and the measured value resulting from the analysis. It is not the purpose of this article to delve into statistical intricacies pertaining to data transformation, the use of linear or nonlinear regression techniques, residual analysis, and so forth. Currently, it is sufficient that an assay purporting to be quantitative in nature must have a demonstrable quantitative relationship between the quantity of material of interest contained in the sample and the measured response. Range is directly related to linearity, and ties in accuracy and precision as well. It represents the lowest and highest quantities of material of interest contained within the samples under analysis that provide data with acceptable accuracy, precision, and linearity. Detection limit represents the least amount of material of interest contained within the sample under analysis that produces a signal exceeding the underlying noise. No assertions pertaining to accuracy, precision, and linearity are necessary at this level of material of interest. For example, if a method is validated to have a detection limit of 3 ng of total protein using Method 3 (I), then a sample containing 3 ng would elicit a signal discernible from underlying noise. It would not be possible to state from such data alone whether there was in fact an exact quantity ng of protein in the sample, only that there were at least 3 ng. Quantitation-limit determination is more demanding in that currently it is necessary to establish the minimum quantity of material of interest contained within the sample that produces a signal that lies within the linear range of data. That is to say, the quantitation limit represents the lowest end of the range. Intermediate precision (ruggedness in USP Chapter (1225) [I]) pertains to the establishment of ' I...the effects of random events on the precision of the analytical procedure" (4). Referring to the previous discussion under accuracy pertaining to error components, intermediate precision considers random error introduced by such factors as specific equipment, analysts, laboratories, days, and so forth. It is not meant to include systematic error (bias). Robustness is probably most directly related to the consideration of conditions under which a validated method is shown to be suitable. This text is very useful in considering robustness: If measurements are susceptible to variations in analytical conditions, the analytical conditions should be suitably controlled or a precautionary statement should be included in the procedure. One consequence of the evaluation of robustness should be that a series of system suitability parameters (e.g., resolution test) is established to ensure that the validity of the analytical procedure is maintained whenever used (4). 152 Pharmaceutical Technoloyy APRIL 2007

5 General requirements for verification One question that may be asked of the compendia is whether a method provided as official (in the compendia or supplements) requires validation. USP Chapter (1225) states:... users of analytical methods described in the USP-NF are not required to validate accuracy and reliability of these methods, but merely verify their suitability under actual conditions of use (1). This text is consistent with the proposal in this article that the term validation be reserved for the process whereby one determines if a given method is suitable for its intended purpose (which must be clearly defined), and that the term verification be reserved for the demonstration that the conditions under which the method is to be performed will be appropriate for the method. Another question may be given that verification involves demonstrating that the conditions to be evaluated are suitable for use with the validated method, how does one go about assessing that? It should be evident that a subset of the determinations performed during the validation would be appropriate. Important conditions to consider include equipment, possible matrix effects (components included in the article to be tested that were not evaluated during the validation), and other conditions for which there is no clear indication provided in the method as to their suitability. A proposed new General Chapter (1226) "Verification of Compendial Procedures" (see reference 9 for a discussion of this chapter) provides some guidance as to how the verification process may be executed, but ultimately the user is responsible for selecting which of the characteristics (data elements) evaluated during the validation should be examined as part of the verification. The user should establish which of those validation characteristics are critical to the successful use of the validated method. Summary There has been some :onfusion about when an analytical method should be validated and when it should be verified. In fact, there have been occasions when the terms have been used interchangeably. It is suggested that the term validation be reserved for the process necessary to demonstrate that a method is suitable for its intended purpose. Effective validation begins with a proper statement of the purpose of the method. This statement should accompany the method validation report, and in some circumstances, such as with Chapter (71) "Sterility Tests" (I), the statement should appear in the text accompanying the method. Depending upon the degree to which robustness is assessed during the validation process, there may be a set of conditions determined that may be suitable for the use of the method, and conditions that are contraindicated. If such conditions have been established, it is helpful for them to accompany the text describing the method (for example, Method 3 in [9]). The term verification should be reserved for the process whereby it is established that the conditions under which an article is to be tested by a validated method are indeed suitable for that method. The verification process might be considered to include a subset of the validation process, as suggested by Figure 1. The characteristics (data elements) of a validation process are contained in several documents, and which of these are incorporated in the validation should be appropriate to the method's intended purpose (and spelled out in the validation protocol.) The characteristics from the validation that are assessed during the verification should be representative of the critical aspects of the method. An example of the verification of the range for Method 3 was provided. Given that verification, as described in this article, is intended to address the suitability of a particular set of conditions for use with a validated method, robustness is not likely to be important for the verification process. For both validation and verification, one must remember the underlying purpose of the method. If the method is from the pharmacopeia and is intended to be used in demonstrating that a pharmacopeial article meets requirements (for which there is a monograph), the method is considered to be validated, and it would be necessary to verify that the test article is suitable for use with the method. If the method is from the pharmacopeia but is not intended for use in satisfying monograph requirements, it may need to be validated relative to the specific nonpharmacopeial purpose. If instead the method is not from the pharmacopeia but is intended to satisfy monograph requirements, it must be validated as providing equivalent results to the pharmacopeial method. Finally, if the nonpharmacopeial method is not intended to satisfy monograph requirements, it must be validated according to its specific purpose, and this would not require comparison to any pharmacopeial method. pr References 1. United States Pharnzacopeia 29-National Formulary 24, United States Pharmacopeial Convention, (2006). 1. Pharmacopeial Forum 32 (2), (Mar.-Apr. 2006). 3. Websterj Seventh New Collegiate Dictionary. (G.& C. Merrian~ Co., Springfield, MA, 1965). 4. International Conference on Harmonization Harmonized Tripartite Guideline, Validation of Analytical Procedures: Text and Methodology, (ICH, Geneva, Switzerland, 2005). 5. FDA, Center for Drug Evaluation and Research, Guidance for lndustry: Analytical Procedures and Methods Validation Chemistry, Manufacturing, and Controls Documentation, (Rockville, MD, Aug. 2000). 6. FDA, Center for Drug Evaluation and Research, Guideline on General Principles of Process Validation, (Rockville, MD, May 1987). 7. FDA, Center for Biologics Evaluation and Research, Guidance for lndustry Quality Systems Approach to Pharmaceutical Current Good Manufacturing Practice Regulations, (Rockville, MD, Sept. 2006). 8. FDA, Office of Regulatory Affairs, Guide to Inspections ofpharma-. ceutical Quality Control Laboratories, (Rockville, MD, July 1993). 9. Pappa eta/., "Developn~ent of a New USP General Information Chapter: Verification of Compendial Procedures." Pharm. Technol. 30 (3), (2006). 154 Pharmaceutical Technology APRIL 2007

á1225ñ VALIDATION OF COMPENDIAL PROCEDURES

á1225ñ VALIDATION OF COMPENDIAL PROCEDURES 1640 á1224ñ Transfer of Analytical Procedures / General Information USP 39 THE ANALYTICAL PROCEDURE The procedure should be written with sufficient detail and explicit instructions, so that a trained analyst

More information

Perspectives on Method Validation: Importance of Adequate Method Validation

Perspectives on Method Validation: Importance of Adequate Method Validation Perspectives on Method Validation: Importance of Adequate Method Validation Heather Bridwell, Vikas Dhingra, Daniel Peckman, Jennifer Roark and Thomas Lehman The appropriate validation of analytical methods

More information

Why Do I Test, What Do I Test & When Do I Test It? Ross Caputo, PhD Chief Technical Officer Eagle Analytical Services

Why Do I Test, What Do I Test & When Do I Test It? Ross Caputo, PhD Chief Technical Officer Eagle Analytical Services Why Do I Test, What Do I Test & When Do I Test It? Ross Caputo, PhD Chief Technical Officer Eagle Analytical Services Disclosures I, Ross Caputo, declare no conflicts of interest, real or apparent, and

More information

GUIDANCE NOTES ON ANALYTICAL METHOD VALIDATION

GUIDANCE NOTES ON ANALYTICAL METHOD VALIDATION ON ANALYTICAL METHOD VALIDATION HSA September 2004 Reproduction prohibited for commercial purposes. Reproduction for internal use is authorised, provided the source is acknowledged. MQA Dir: DISK1\GUIDE-MQA-012A-004.doc

More information

Thank You to United States Pharmacopeia for Their Sponsorship and Assistance

Thank You to United States Pharmacopeia for Their Sponsorship and Assistance Use of Measurement Uncertainty in Testing a Drug Substance M.L. Jane Weitzel Quality Analysis Consultants mljweitzel@msn.com Eurachem/CITAC Workshop June 2011 Thank You to United States Pharmacopeia for

More information

BRIEFING. . Over time, 466 may be used less frequently and may be withdrawn.

BRIEFING. . Over time, 466 may be used less frequently and may be withdrawn. Page 1 of 13 BRIEFING 1086 USP 37 page 828. As part of an ongoing monograph modernization initiative, the United States Pharmacopeial Convention (USP) is updating this general chapter, 1086 Impurities

More information

Validation/Verification of Test Methods An FDA Perspective. Laure H. Kairawicz, Ph.D. Senior Scientist Expert Witness

Validation/Verification of Test Methods An FDA Perspective. Laure H. Kairawicz, Ph.D. Senior Scientist Expert Witness Validation/Verification of Test Methods An FDA Perspective Laure H. Kairawicz, Ph.D. Senior Scientist Expert Witness FD & C Act Overview Definition of drugs What cgmps are Finished Pharmaceuticals cgmp

More information

Established Conditions: Reportable CMC Changes for Approved Drug and Biologic Products Guidance for Industry

Established Conditions: Reportable CMC Changes for Approved Drug and Biologic Products Guidance for Industry Established Conditions: Reportable CMC Changes for Approved Drug and Biologic Products Guidance for Industry DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments

More information

Analytical Method Transfer Program. Richard B. Nguyen. Associate Scientific Liaison, Chemical Medicines, USP

Analytical Method Transfer Program. Richard B. Nguyen. Associate Scientific Liaison, Chemical Medicines, USP Analytical Method Transfer Program Richard B. Nguyen. Associate Scientific Liaison, Chemical Medicines, USP Outline Requirements for an AMT Program Develop Your AMT Program Qualify Your AMT Program On-going

More information

Extending Beyond Use Dating for Compounded Preparations Webinar Q&A

Extending Beyond Use Dating for Compounded Preparations Webinar Q&A Stability Studies 1. If potency over time studies are not acceptable to extend BUD, then why is it offered? Potency point-in-time studies only indicate the potency of a compounded preparation at that specific

More information

VALIDATION OF ANALYTICAL PROCEDURES: METHODOLOGY *)

VALIDATION OF ANALYTICAL PROCEDURES: METHODOLOGY *) VALIDATION OF ANALYTICAL PROCEDURES: METHODOLOGY *) Guideline Title Validation of Analytical Procedures: Methodology Legislative basis Directive 75/318/EEC as amended Date of first adoption December 1996

More information

Extending Beyond Use Dating for Compounded Preparations Webinar Q&A

Extending Beyond Use Dating for Compounded Preparations Webinar Q&A Stability Studies 1. If potency over time studies are not acceptable to extend BUD, then why is it offered? Potency point-in-time studies only indicate the potency of a compounded preparation at that specific

More information

9/2/2014. USP Monograph Modernization. Todays topics. USP basic. Todays topics. - USP basic. - USP publications. - USP monograph modernization

9/2/2014. USP Monograph Modernization. Todays topics. USP basic. Todays topics. - USP basic. - USP publications. - USP monograph modernization USP Monograph Modernization Procedure Review and Development Donald Min 2 USP basic Since USP's founding in 1820, our operations have grown exponentially: from 11 volunteers collaborating from their respective

More information

Proposed New USP General Chapter: The Analytical Procedure Lifecycle 1220

Proposed New USP General Chapter: The Analytical Procedure Lifecycle 1220 Page 1 of 9 STIMULI TO THE REVISION PROCESS Stimuli articles do not necessarily reflect the policies of the USPC or the USP Council of Experts Proposed New USP General Chapter: The Analytical Procedure

More information

Microbiology Testing: USP requirements for Sterile and Nonsterile Preparations Webinar Q&A

Microbiology Testing: USP requirements for Sterile and Nonsterile Preparations Webinar Q&A USP Antimicrobial Effectiveness Testing Microbiology Testing: Webinar Q&A 1. If a base ingredient is designed for the purpose of compounding a specific type of preparation does this forgo the necessity

More information

LABORATORY COMPLIANCE

LABORATORY COMPLIANCE 1 LABORATORY COMPLIANCE Jeanne Moldenhauer Vectech Pharmaceutical Consultants, Inc. Farmington Hills, MI INTRODUCTION Implementation of the Systems-Based Inspection Guideline for drug manufacturers in

More information

VICH Topic GL2 (Validation: Methodology) GUIDELINE ON VALIDATION OF ANALYTICAL PROCEDURES: METHODOLOGY

VICH Topic GL2 (Validation: Methodology) GUIDELINE ON VALIDATION OF ANALYTICAL PROCEDURES: METHODOLOGY The European Agency for the Evaluation of Medicinal Products Veterinary Medicines Evaluation Unit CVMP/VICH/591/98-FINAL London, 10 December 1998 VICH Topic GL2 (Validation: Methodology) Step 7 Consensus

More information

Analytical Methods Development and Validation

Analytical Methods Development and Validation Understanding and Implementing Efficient Analytical Methods Development and Validation Jay Breaux, Kevin Jones, and Pierre Boulas Analytical methods development and validation play important roles in the

More information

Commentary Pharmacopeial Forum 35(5) Sept.-Oct Interim Revision Announcements to USP 33-NF 28 Reissue

Commentary Pharmacopeial Forum 35(5) Sept.-Oct Interim Revision Announcements to USP 33-NF 28 Reissue Commentary Pharmacopeial Forum 35(5) Sept.-Oct. 2009 Interim Revision Announcements to USP 33-NF 28 Reissue In accordance with USP s Rules and Procedures of the Council of Experts, USP publishes all proposed

More information

STIMULI TO THE REVISION PROCESS. Bioassay Glossary

STIMULI TO THE REVISION PROCESS. Bioassay Glossary Vol. 32(4) [July Aug. 2006] of the USPC or the USP Council of Experts 1359 Bioassay Glossary Robert Singer, PDL Biopharma; David M. Lansky, Lansky Consulting; and Walter W. Hauck, Thomas Jefferson University

More information

Recent USP Updates May, 2013

Recent USP Updates May, 2013 Recent USP Updates May, 2013 Don Singer GSK Bioburden Control of Non-sterile Drug Substances and Products The chapter emphasizes control as a risk mitigation strategy The chapter recommends a risk-based

More information

Guidance for Industry

Guidance for Industry Guidance for Industry Investigating Out-of-Specification (OOS) Test Results for Pharmaceutical Production U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation

More information

TEMPLATE FOR AN EXAMPLE METHODS VALIDATION STANDARD OPERATING PROCEDURE (SOP)

TEMPLATE FOR AN EXAMPLE METHODS VALIDATION STANDARD OPERATING PROCEDURE (SOP) APPENDIX II TEMPLATE FOR AN EXAMPLE METHODS VALIDATION STANDARD OPERATING PROCEDURE (SOP) SOP EXAMPLE TEMPLATE 1. PURPOSE 1.1 This procedure is intended to provide general guidelines for the validation

More information

Validation of Analytical Methods used for the Characterization, Physicochemical and Functional Analysis and of Biopharmaceuticals.

Validation of Analytical Methods used for the Characterization, Physicochemical and Functional Analysis and of Biopharmaceuticals. Validation of Analytical Methods used for the Characterization, Physicochemical and Functional Analysis and of Biopharmaceuticals. 1 Analytical Method Validation: 1..1 Philosophy: Method validation is

More information

Analytical Procedures and Methods Validation for Drugs and Biologics

Analytical Procedures and Methods Validation for Drugs and Biologics Analytical Procedures and Methods Validation for Drugs and Biologics Lucinda (Cindy) Buhse, Ph. D. Acting Director, Office of Testing and Research Office of Pharmaceutical Science CDER, FDA CHPA Quality

More information

Understanding the Characteristics and Establishing Acceptance Criteria for Analytical Methods Validation

Understanding the Characteristics and Establishing Acceptance Criteria for Analytical Methods Validation Understanding the Characteristics and Establishing Acceptance Criteria for Analytical Methods Validation Ying Verdi IVT LAB WEEK EUROPE June 2017 Partners in Health Since 1919 Regulatory View of Method

More information

Quality of raw materials and manufacturing of advanced therapies. Fouad Atouf, Ph.D. Head, Global Biologics July 12, 2018

Quality of raw materials and manufacturing of advanced therapies. Fouad Atouf, Ph.D. Head, Global Biologics July 12, 2018 Quality of raw materials and manufacturing of advanced therapies Fouad Atouf, Ph.D. Head, Global Biologics July 12, 2018 Evolution of the compendia 1820: a single recipe book 2018: Procedures and acceptance

More information

Lifecycle Management Concepts to analytical Procedures: A compendial perspective. Horacio Pappa, Ph.D. Director - General Chapters U.S.

Lifecycle Management Concepts to analytical Procedures: A compendial perspective. Horacio Pappa, Ph.D. Director - General Chapters U.S. Lifecycle Management Concepts to analytical Procedures: A compendial perspective Horacio Pappa, Ph.D. Director - General Chapters U.S. Pharmacopeia USP Definitions Validation of Compendial Procedures

More information

Validation, Verification and Transfer of Analytical Methods (Understanding and implementing guidelines from FDA/EMA, USP and ICH)

Validation, Verification and Transfer of Analytical Methods (Understanding and implementing guidelines from FDA/EMA, USP and ICH) Validation, Verification and Transfer of Analytical Methods (Understanding and implementing guidelines from FDA/EMA, USP and ICH) *** LIMITED TIME OFFER: FREE $100 AMAZON GIFT CARD! *** REGISTER TODAY!

More information

Secundum Artem. USP Chapter <795> Pharmaceutical Compounding - Nonsterile Preparations INTRODUCTION BACKGROUND VOLUME 13 NUMBER 4

Secundum Artem. USP Chapter <795> Pharmaceutical Compounding - Nonsterile Preparations INTRODUCTION BACKGROUND VOLUME 13 NUMBER 4 VOLUME 13 NUMBER 4 Secundum Artem Current & Practical Compounding Information for the Pharmacist. USP Chapter Pharmaceutical Compounding - Nonsterile Preparations GOALS AND OBJECTIVES Goal: The goal

More information

INTERNATIONAL RESEARCH JOURNAL OF PHARMACY ISSN Review Article

INTERNATIONAL RESEARCH JOURNAL OF PHARMACY  ISSN Review Article INTERNATIONAL RESEARCH JOURNAL OF PHARMACY www.irjponline.com ISSN 2230 8407 Review Article INTRODUCTION AND GENERAL OVERVIEW OF PHARMACEUTICAL PROCESS VALIDATION: A REVIEW Pandita Rachna* 1, Rana A C

More information

á1058ñ ANALYTICAL INSTRUMENT QUALIFICATION

á1058ñ ANALYTICAL INSTRUMENT QUALIFICATION USP 41 General Information / á1058ñ 1 á1058ñ ANALYTICAL INSTRUMENT QUALIFICATION INTRODUCTION A large variety of analytical instruments, ranging from a simple apparatus to complex computerized systems,

More information

Validation of Impurity Methods, Part I

Validation of Impurity Methods, Part I 626 LCGC NORTH AMERICA VOLUME 21 NUMBER 7 JULY 2003 www.chromatographyonline.com Validation Viewpoint John D. Orr, Ira S. Krull, and Michael E. Swartz This column is the first installment in a two-part

More information

Guidance. Media Fills for Validation of Aseptic Preparations for Positron Emission Tomography (PET) Drugs DRAFT GUIDANCE

Guidance. Media Fills for Validation of Aseptic Preparations for Positron Emission Tomography (PET) Drugs DRAFT GUIDANCE Guidance Media Fills for Validation of Aseptic Preparations for Positron Emission Tomography (PET) Drugs DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and

More information

Update to USP <621> Chromatography: What does this mean? USP 37 NF 32 1S Current as of August 2014

Update to USP <621> Chromatography: What does this mean? USP 37 NF 32 1S Current as of August 2014 Update to USP Chromatography: What does this mean? USP 37 NF 32 1S Current as of August 2014 2015 Waters Corporation 1 What is the USP-NF? The United States Pharmacopeia National Formulary (USP-NF)

More information

3. Equipment Cleaning Validation for Active Pharmaceutical Ingredients (APIs) 8. Process Validation for Active Pharmaceutical Ingredients (API)

3. Equipment Cleaning Validation for Active Pharmaceutical Ingredients (APIs) 8. Process Validation for Active Pharmaceutical Ingredients (API) Title: Good Working Practice Validation Requirements Practice Number: 06 Prepared by: Date: Supersedes: Checked by: Date: Date Issued: Approved by: Date: Review Date: Topics: 1. Biological Test Methods

More information

A2LA. R231 Specific Requirements: Threat Agent Testing Laboratory Accreditation Program. December 6, 2017

A2LA. R231 Specific Requirements: Threat Agent Testing Laboratory Accreditation Program. December 6, 2017 Laboratory Page 1 of 17 Laboratory December 6, 2017 2017 by A2LA All rights reserved. No part of this document may be reproduced in any form or by any means without the prior written permission of A2LA.

More information

ICH Q2(R1) A Primer. cgmp. GxP PIC/S SOP ISO QA/QC LOD/LOQ. Validation of Analytical Methods API EP FDA OECD GCP

ICH Q2(R1) A Primer. cgmp. GxP PIC/S SOP ISO QA/QC LOD/LOQ. Validation of Analytical Methods API EP FDA OECD GCP USP ICH Q2(R1) A Primer GxP cgmp PIC/S SOP ISO 17025 QA/QC LOD/LOQ API EP Validation of Analytical Methods FDA OECD GCP Validation of Analytical Methods Ludwig Huber Contents Preface...............................................

More information

Analytical Procedures and Methods Validation for Drugs and Biologics

Analytical Procedures and Methods Validation for Drugs and Biologics Final Guidance for Industry Analytical Procedures and Methods Validation for Drugs and Biologics Analytical procedures and Method Validation June 21, 2016 Lokesh Bhattacharyya Chief, LACBRP/DBSQC OCBQ/CBER/FDA

More information

Common Issues in Qualification and Validation of Analytical Procedures

Common Issues in Qualification and Validation of Analytical Procedures Common Issues in Qualification and Validation of Analytical Procedures Alexey Khrenov, PhD OTAT/CBER/FDA CMC Strategy Forum January 29, 2018 - Washington, DC Disclaimer These comments are an informal communication

More information

USP <1223> Revision and the Alternative Microbiological Methods Workshop Tony Cundell, Ph. D. Consulting Microbiologist, Scarsdale, New York, USA

USP <1223> Revision and the Alternative Microbiological Methods Workshop Tony Cundell, Ph. D. Consulting Microbiologist, Scarsdale, New York, USA USP Revision and the Alternative Microbiological Methods Workshop Tony Cundell, Ph. D. Consulting Microbiologist, Scarsdale, New York, USA September, 2015 biomerieux Meeting 1 Presentation Outline

More information

QbD Concepts Applied to Qualification and Transfer of Analytical Methods

QbD Concepts Applied to Qualification and Transfer of Analytical Methods QbD Concepts Applied to Qualification and Transfer of Analytical Methods CMC Strategy Forum Latin America - 2014 Patrick Swann Senior Director Technical Development QbD = Quality by Design QbD - A systematic

More information

Guidance for Industry

Guidance for Industry Guidance for Industry for the Submission Documentation for Sterilization Process Validation in Applications for Human and Veterinary Drug Products Center for Drug Evaluation and Research (CDER) Center

More information

STIMULI TO THE REVISION PROCESS

STIMULI TO THE REVISION PROCESS Page 1 of 6 STIMULI TO THE REVISION PROCESS Stimuli articles do not necessarily reflect the policies of the USPC or the USP Council of Experts USP's Nomenclature Initiatives Angela G. Long, M.S.; Andrzej

More information

International Journal of Pharma and Bio Sciences DEVELOPMENT OF ACCELERATED STABILITY PROTOCOL FOR SILDENAFIL TABLETS A EUROPEAN PERSPECTIVE REVIEW

International Journal of Pharma and Bio Sciences DEVELOPMENT OF ACCELERATED STABILITY PROTOCOL FOR SILDENAFIL TABLETS A EUROPEAN PERSPECTIVE REVIEW International Journal of Pharma and Bio Sciences DEVELOPMENT OF ACCELERATED STABILITY PROTOCOL FOR SILDENAFIL TABLETS A EUROPEAN PERSPECTIVE REVIEW SUKHDEV SINGH *1 AND JASBIR SINGH 2 1 Rayat Institute

More information

Regulatory Implications for Global Manufacturing Development of Regenerative Medicines

Regulatory Implications for Global Manufacturing Development of Regenerative Medicines Regulatory Implications for Global Manufacturing Development of Regenerative Medicines Katherine Tsokas, JD June 2017 Global Regulatory Affairs Janssen Research & Development, LLC Jessica Riley, Shells

More information

Available online at ScienceDirect. Procedia Engineering 132 (2015 )

Available online at  ScienceDirect. Procedia Engineering 132 (2015 ) Available online at www.sciencedirect.com ScienceDirect Procedia Engineering 132 (2015 ) 811 815 The Manufacturing Engineering Society International Conference, MESIC 2015 Metrological Regulations for

More information

INTRODUCTION TO THE QUALITY SYSTEMS APPROACH TO CGMP COMPLIANCE

INTRODUCTION TO THE QUALITY SYSTEMS APPROACH TO CGMP COMPLIANCE 001_005.qxd 24/2/06 19:46 Page 1 CHAPTER 1 INTRODUCTION TO THE QUALITY SYSTEMS APPROACH TO CGMP COMPLIANCE 1.1 OVERVIEW OF QUALITY SYSTEMS The Food and Drug Administration (FDA) mandates that a drug firm,

More information

International Pharmaceutical Excipients Council Of The Americas

International Pharmaceutical Excipients Council Of The Americas October 6, 2008 Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm. 1061 Rockville, MD 20852 Subject: FDA Draft Guidance for Industry, Residual Solvents in Drug

More information

Method validation is the process used to confirm that

Method validation is the process used to confirm that Developing a Validation Strategy for Rapid Microbiological Methods Michael J. Miller, Ph.D. President, Microbiology Consultants, LLC All analytical methods need to be validated prior to their introduction

More information

Method Validation Studies How GLP Interacts With Guidance Documents

Method Validation Studies How GLP Interacts With Guidance Documents Method Validation Studies How GLP Interacts With Guidance Documents Steven S. Kuwahara ROBERT GEORGE YOUNG/GETTY IMAGES GLP Forum addresses topics of interest associated with good laboratory practices.

More information

Table of Contents. Legal Notices... 61

Table of Contents. Legal Notices... 61 Notice This manual provides information to excipient manufacturers who intend to participate in the United States Pharmacopeia Ingredient Verification Program for Excipients (USP IVP-E or Program). The

More information

Elementverunreinigungen in Pharmaprodukten Neue Limits und Verfahren zur Bestimmung nach USP

Elementverunreinigungen in Pharmaprodukten Neue Limits und Verfahren zur Bestimmung nach USP Elementverunreinigungen in Pharmaprodukten Neue Limits und Verfahren zur Bestimmung nach USP Ludwig Huber, Ph.D Chief Advisor, Global FDA Compliance for Ludwig Huber Phone: +49 7902 980582 E-mail: Ludwig_Huber@Labcompliance.com

More information

Subpart B Organization and Personnel, 21 CFR Responsibilities of the quality control unit.

Subpart B Organization and Personnel, 21 CFR Responsibilities of the quality control unit. FDA inspections continue to focus on CGMP violations related to basic GMP controls. A survey of Warning Letters issued in 2013 on CMC (Chemistry / Manufacturing / Controls) violations reveals an emphasis

More information

Examples of regulatory expectations for analytical characterization and testing

Examples of regulatory expectations for analytical characterization and testing Examples of regulatory expectations for analytical characterization and testing AT Europe 2016, 18 March 2016 Vicki Venizelos Quality RA B.V. Leiden, the Netherlands Overview What are the regulatory expectations?

More information

PROCESS VALIDATION ROCHAPON WACHAROTAYANKUN, PH.D.

PROCESS VALIDATION ROCHAPON WACHAROTAYANKUN, PH.D. Basic GMP Requirement PROCESS VALIDATION ROCHAPON WACHAROTAYANKUN, PH.D. Topic Process validation What and Why? Principle of process validation Manufacturing process validation Aseptic process validation

More information

The International Harmonization of the Compendial Microbial Limits Tests A Cautionary Tale of Compendial Participation

The International Harmonization of the Compendial Microbial Limits Tests A Cautionary Tale of Compendial Participation MI C R O BI O L O GY T O PIC S The International Harmonization of the Compendial Microbial Limits Tests A Cautionary Tale of Compendial Participation Scott Sutton image source, medicalrf.com/getty images

More information

Experience with Health Canada s Approach for Post-Approval Changes. Kiran Krishnan Vice President US Regulatory Affairs September 2014

Experience with Health Canada s Approach for Post-Approval Changes. Kiran Krishnan Vice President US Regulatory Affairs September 2014 Experience with Health Canada s Approach for Post-Approval Changes Kiran Krishnan Vice President US Regulatory Affairs September 2014 Important Quotes to consider Dr. Janet Woodcock on desired state: A

More information

Pharmaceutical Reference Standards: Overview and Role in Global Harmonization

Pharmaceutical Reference Standards: Overview and Role in Global Harmonization Matthew Borer, Ph.D., Advisor Pharmaceutical Reference Standards: Overview and Role in Global Harmonization 3rd DIA China Annual Meeting Beijing, China, 16-18 May, 2011 What is a Pharmaceutical Reference

More information

October 10, Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm Rockville, MD 20852

October 10, Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm Rockville, MD 20852 October 10, 2017 Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm. 1061 Rockville, MD 20852 Re: Docket No. FDA 2017 D 2802: Chemistry, Manufacturing, and Controls

More information

1201 Maryland Avenue SW, Suite 900, Washington, DC ,

1201 Maryland Avenue SW, Suite 900, Washington, DC , 1201 Maryland Avenue SW, Suite 900, Washington, DC 20024 202-962-9200, www.bio.org 15 July 2010 European Commission Enterprise and Industry Directorate General Consumer Goods, Pharmaceuticals B-1049 Brussels

More information

Phase Appropriate GMPs for IMPs. Presented by: Karen S. Ginsbury For: IFF, October 31, Nov 02, 2017

Phase Appropriate GMPs for IMPs. Presented by: Karen S. Ginsbury For: IFF, October 31, Nov 02, 2017 Phase Appropriate GMPs for IMPs Presented by: Karen S. Ginsbury For: IFF, October 31, Nov 02, 2017 1 Lets start with References https://mhrainspectorate.blog.gov.uk/2016/0 5/20/manufacture-of-investigationalmedicinal-products-frequently-askedquestions/

More information

The Most Probable Number Method and Its Use in QC Microbiology

The Most Probable Number Method and Its Use in QC Microbiology The Most Probable Number Method and Its Use in QC Microbiology Scott Sutton "Microbiology Topics" discusses various topics in microbiology of practical use in validation and compliance. We intend this

More information

Reference Standard Characterization. Steve Lane. General Manager, NSF Reference Standards.

Reference Standard Characterization. Steve Lane. General Manager, NSF Reference Standards. Reference Standard Characterization Steve Lane General Manager, NSF Reference Standards www.nsf-rs.org Regulatory Bodies will require that an Excipient: Be safe in the amount or dose used Meet applicable

More information

Synopsis: FDA Process Validation Guidance

Synopsis: FDA Process Validation Guidance Synopsis: FDA Process Validation Guidance This synopsis is a comparison of the draft version 2008 and the final version 2011 of the U.S. FDA Guidance Process Validation: General Principles and Practices.

More information

Validation & Transfer of Methods for

Validation & Transfer of Methods for Validation & Transfer of Methods for Course option 1: Pharmaceutical Analysis, or Course option 2: Biopharmaceutical Analysis TRAINING COURSE This course will provide you with the requisite scientific

More information

1 Analytical Validation within the Pharmaceutical Lifecycle

1 Analytical Validation within the Pharmaceutical Lifecycle 1 1 Analytical Validation within the Pharmaceutical Lifecycle Phil Nethercote and Joachim Ermer 1.1 Development of Process and Analytical Validation Concepts The concept of validation in the pharmaceutical

More information

FUTURE-PROOF SOLUTIONS FOR REGULATED LABORATORIES IN THE FACE OF CHANGING USP <621> GUIDELINES

FUTURE-PROOF SOLUTIONS FOR REGULATED LABORATORIES IN THE FACE OF CHANGING USP <621> GUIDELINES FUTURE-PROOF SOLUTIONS FOR REGULATED LABORATORIES IN THE FACE OF CHANGING USP GUIDELINES How to use UPLC technology within allowable adjustments to improve QC laboratory throughput For many in the

More information

USP Standards for Ancillary Materials

USP Standards for Ancillary Materials Quality Standards for Medicines, Supplements, and Food Ingredients throughout the World USP Standards for Ancillary Materials 8 th Annual Somatic Cell Therapy Symposium September 22-24 2008 Fouad Atouf,

More information

with an Example of for an HPLC Procedure

with an Example of for an HPLC Procedure Peer Reviewed: Analytical Procedure Journal of Validation Technology The Use of the Analytical Target Profile in the Lifecycle of an Analytical Procedure with an Example of for an HPLC Procedure Jane Weitzel,

More information

Guide to Fulfillment of Validation and Verification of Examination Requirements

Guide to Fulfillment of Validation and Verification of Examination Requirements DIAGNOSTIC ACCREDITATION PROGRAM College of Physicians and Surgeons of British Columbia 300 669 Howe Street Telephone: 604-733-7758 ext. 2635 Vancouver BC V6C 0B4 Toll Free: 1-800-461-3008 (in BC) www.cpsbc.ca

More information

Changes to a Potency Bioassay for Biotechnology Products: a Regulatory Perspective Kathleen A. Clouse, Ph.D., Director Division of Monoclonal Antibodi

Changes to a Potency Bioassay for Biotechnology Products: a Regulatory Perspective Kathleen A. Clouse, Ph.D., Director Division of Monoclonal Antibodi Changes to a Potency Bioassay for Biotechnology Products: a Regulatory Perspective Kathleen A. Clouse, Ph.D., Director Division of Monoclonal Antibodies Office of Biotechnology Products Center for Drug

More information

Validation of Thin Layer Chromatographic Procedures

Validation of Thin Layer Chromatographic Procedures Validation of Thin Layer Chromatographic Procedures International Symposium for High-Performance Thin-Layer Chromatography HPTLC 2011 July 7th, 2011, Basle Topics ICH Q2(R1) and nothing else? Other guidance

More information

European Medicines Agency Evaluation of Medicines for Human Use

European Medicines Agency Evaluation of Medicines for Human Use European Medicines Agency Evaluation of Medicines for Human Use London, 22 February 2006 EMEA/CHMP/BWP/49348/2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON SIMILAR BIOLOGICAL MEDICINAL

More information

Role of USP Monographs and. General Chapters. Steve Zigler, Ph.D.

Role of USP Monographs and. General Chapters. Steve Zigler, Ph.D. Role of USP Monographs and General Chapters Steve Zigler, Ph.D. Siemens PETNET Solutions USP Disclosure I have served as a USP volunteer in the area of PET drugs for 15 years Member of various Expert Committees

More information

Method Development and Validation for Online UV-Dissolution Methods Using Fiber-Optic Technology

Method Development and Validation for Online UV-Dissolution Methods Using Fiber-Optic Technology Technical Overview Method Development and Validation for Online UV-Dissolution Methods Using Fiber-Optic Technology Introduction Online fiber-optic and multicell UV-dissolution systems have become increasingly

More information

Pharmaceutical Compounding Sterile and Nonsterile Preparations. Jeanne Sun, PharmD

Pharmaceutical Compounding Sterile and Nonsterile Preparations. Jeanne Sun, PharmD Pharmaceutical Compounding Sterile and Nonsterile Preparations Jeanne Sun, PharmD Agenda Legal Framework Overview Pharmaceutical Compounding Nonsterile Preparations Pharmaceutical Compounding

More information

Challenges of Analytical Method Transfer in the Pharmaceutical Industry

Challenges of Analytical Method Transfer in the Pharmaceutical Industry Challenges of Analytical Method Transfer in the Pharmaceutical Industry White Paper Author: Steve Alley, Technical Specialist 1 Contents Introduction 2 Method Transfer Team 3 Identify Methods 4 Gap Analysis

More information

RE: Draft Annex 2: Manufacture of Biological Medicinal Products for Human Use

RE: Draft Annex 2: Manufacture of Biological Medicinal Products for Human Use 1201 Maryland Avenue SW, Suite 900, Washington, DC 20024 202-962-9200, www.bio.org 14 March 2008 European Commission Enterprise and Industry Directorate-General B-1049 Brussels Belgium BY EMAIL TO entr-gmp@ec.ec.europa.eu

More information

Guidelines for Process Validation of Pharmaceutical Dosage Forms

Guidelines for Process Validation of Pharmaceutical Dosage Forms Guidelines for Process Validation of Pharmaceutical Dosage Forms Version 2.1 Date issued 21/02/2010 Date of implementation 21/05/2010 31 August 2010 Page 1 of 20 Guidelines for Process Validation of Pharmaceutical

More information

Regulatory Perspective on Assuring Ingredient Quality

Regulatory Perspective on Assuring Ingredient Quality Regulatory Perspective on Assuring Ingredient Quality PQRI Conference December 15, 2009 Rockville, MD Steven M. Wolfgang, Ph.D., Acting Associate Director, Regulatory Science US Food and Drug Administration

More information

1225 VALIDATION OF lytical performance characteristics that should be considered COMPENDIAL PROCEDURES

1225 VALIDATION OF lytical performance characteristics that should be considered COMPENDIAL PROCEDURES USP 36 General Information / 1225 Validation of Compendial Procedures 1 formance characteristics of the procedure meet the requirements for the intended analytical applications. Typical ana- 1225 VALIDATION

More information

TECHNICAL GUIDANCE FOR THE VALIDATION OF METHODS USED BY CHEMICAL LABORATORIES IN THE FOOD, WATER AND RELATED INDUSTRIES

TECHNICAL GUIDANCE FOR THE VALIDATION OF METHODS USED BY CHEMICAL LABORATORIES IN THE FOOD, WATER AND RELATED INDUSTRIES TECHNICAL GUIDANCE FOR THE VALIDATION OF METHODS USED BY CHEMICAL LABORATORIES IN THE FOOD, WATER AND RELATED INDUSTRIES Approved By: Chief Executive Officer: Ron Josias Senior Manager: Christinah Leballo

More information

The Parenteral Drug Association

The Parenteral Drug Association C O N F E R E N C E R E P O R T Equipment Cleaning Microbial Control Issues By Destin A. LeBlanc, M.A. Cleaning Validation Technologies Validation: The Parenteral Drug Association (PDA) spring conference

More information

Strategies for IND Filing Success: Chemistry, Manufacturing and Controls

Strategies for IND Filing Success: Chemistry, Manufacturing and Controls Strategies for IND Filing Success: Chemistry, Manufacturing and Controls October 21, 2016 Presented by: Sharon Ayd, Ph.D., MBA Chief Scientific Officer and SVP, Pharmaceuticals document contains proprietary

More information

Automating HPLC and GC Analytical Method Validation Fusion AE Software Program White Paper

Automating HPLC and GC Analytical Method Validation Fusion AE Software Program White Paper Automating HPLC and GC Analytical Method Validation Fusion AE Software Program White Paper Varian, Inc. 2700 Mitchell Drive Walnut Creek, California 94598, USA www.varianinc.com Introduction Chromatographic

More information

Data Integrity Prioritization and Gap Analysis to Prove Data Integrity

Data Integrity Prioritization and Gap Analysis to Prove Data Integrity Data Integrity Prioritization and Gap Analysis to Prove Data Integrity Oct 9 th 2018 Speakers Alex Brindle Principal Consultant with DPS. Alex holds a B.Sc. in Chemistry, a M.Sc. in Analytical Science

More information

1225 Eye Street NW, Ste. 400 Washington, DC 20005

1225 Eye Street NW, Ste. 400 Washington, DC 20005 1225 Eye Street NW, Ste. 400 Washington, DC 20005 30 June 2005 EMEA Biologics Working Party Secretariat Attention: Linda Olsson European Medicines Agency 7 Westferry Circus Canary Wharf London E14 4HB

More information

STANDARD OPERATING PROCEDURES. Handling and working with Analytical Standards

STANDARD OPERATING PROCEDURES. Handling and working with Analytical Standards Page: 1 of 6 1.Purpose The purpose of this Standard Operating Procedure is to establish a standardized procedure of using United States Pharmacopoeia (USP) standards, detailing the procedure of qualification,

More information

Contents. Contents (13) 1 Production (23)

Contents. Contents (13) 1 Production (23) 1 Production (23) 1.A Sanitation (27) 1.A.1 Organisational prerequisites (27) 1.A.2 Sources of contamination (28) 1.A.3 Responsibilities and implementation (29) 1.B Personnel hygiene (31) 1.B.1 Clothing

More information

Ancillary Materials for Cell & Tissue Therapies Definitions, US Regulatory Approach, and USP s Risk-Tiered Approach

Ancillary Materials for Cell & Tissue Therapies Definitions, US Regulatory Approach, and USP s Risk-Tiered Approach USP/ISCT Workshop 2012 Seattle, WA, USA Ancillary Materials for Cell & Tissue Therapies Definitions, US Regulatory Approach, and USP s Risk-Tiered Approach Elizabeth Read, MD Head of Product Development

More information

PLUS MAKE PAPER A THING OF THE PAST CONTROLLED RELEASE QUALITY CONTROL IMAGING RAPID MICROBIO ROI

PLUS MAKE PAPER A THING OF THE PAST CONTROLLED RELEASE QUALITY CONTROL IMAGING RAPID MICROBIO ROI Volume 11 Number 3 JUNE 2009 PLUS MAKE PAPER A THING OF THE PAST CONTROLLED RELEASE QUALITY CONTROL IMAGING RAPID MICROBIO ROI www.pharmaquality.com Cover Story By Eric A. Lingenfelter, Henry L. Evans,

More information

Automating HPLC and GC Analytical Method Validation Fusion AE Software Program White Paper

Automating HPLC and GC Analytical Method Validation Fusion AE Software Program White Paper Automating HPLC and GC Analytical Method Validation Fusion AE Software Program White Paper S-Matrix Corporation 1594 Myrtle Avenue Eureka, CA 95501, USA www.smatrix.com Introduction Chromatographic analytical

More information

USP <1116> and Contamination

USP <1116> and Contamination USP and Contamination Recovery Rates Scott Sutton ABSTRACT United States Pharmacopeia (USP) "Microbiological Control and Monitoring of Aseptic Processing Environments" approaches analysis

More information

Excipients Facing Increased Scrutiny How to Use Secondary Reference Standards to Help Maintain Regulatory Compliance

Excipients Facing Increased Scrutiny How to Use Secondary Reference Standards to Help Maintain Regulatory Compliance Excipients Facing Increased Scrutiny How to Use Secondary Reference Standards to Help Maintain Regulatory Compliance by Tom Savage, NSF International Since 2008, when patient deaths were first linked to

More information

Journal of Chemical and Pharmaceutical Research

Journal of Chemical and Pharmaceutical Research Available online www.jocpr.com Journal of Chemical and Pharmaceutical Research ISSN No: 0975-7384 CODEN(USA): JCPRC5 J. Chem. Pharm. Res., 2011, 3(6):88-98 Conduct of Inspections for Pharmaceutical Manufactures

More information

CC: Richard Levy, PDA; Denyse Baker, PDA

CC: Richard Levy, PDA; Denyse Baker, PDA Bethesda Towers 4350 East West Highway Suite 150 Bethesda, MD 20814 USA Tel: +1 (301) 656-5900 Fax: +1 (301) 986-0296 www.pda.org OFFICERS Chair Harold Baseman ValSource Chair-Elect Martin VanTrieste Amgen

More information

Proposed Revision of USP General Chapter Radiopharmaceuticals for Positron Emission Tomography Compounding <823>

Proposed Revision of USP General Chapter Radiopharmaceuticals for Positron Emission Tomography Compounding <823> Proposed Revision of USP General Chapter Radiopharmaceuticals for Positron Emission Tomography Compounding Ravi Ravichandran, Ph.D. Steve Zigler, Ph.D. February 21, 2011 Agenda Rationale for the

More information

EVALUATION OF PATIENT-RELATED RISKS RESULTING FROM METHOD PERFORMANCES IN ROUTINE QC TESTING

EVALUATION OF PATIENT-RELATED RISKS RESULTING FROM METHOD PERFORMANCES IN ROUTINE QC TESTING LIFE SCIENCE I TECHNICAL BULLETIN OCTOBER 2013 EVALUATION OF PATIENT-RELATED RISKS RESULTING FROM METHOD PERFORMANCES IN ROUTINE QC TESTING AUTHOR: GERALD DE FONTENAY, GLOBAL PROJECT MANAGER, SGS LIFE

More information

CONCEPT PAPER FOR COMMENT

CONCEPT PAPER FOR COMMENT April 2017 Draft document for comment 1 2 3 4 5 6 7 8 CONCEPT PAPER FOR COMMENT TRANSITION FROM MICROBIOLOGICAL TO PHYSICOCHEMICAL ASSAYS IN MONOGRAPHS ON CAPREOMYCIN ACTIVE PHARMACEUTICAL INGREDIENTS

More information